BR112022002894A2 - Composição farmacêutica usada para um paciente tendo marcador genético específico - Google Patents

Composição farmacêutica usada para um paciente tendo marcador genético específico

Info

Publication number
BR112022002894A2
BR112022002894A2 BR112022002894A BR112022002894A BR112022002894A2 BR 112022002894 A2 BR112022002894 A2 BR 112022002894A2 BR 112022002894 A BR112022002894 A BR 112022002894A BR 112022002894 A BR112022002894 A BR 112022002894A BR 112022002894 A2 BR112022002894 A2 BR 112022002894A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
patient
genetic marker
composition used
specific genetic
Prior art date
Application number
BR112022002894A
Other languages
English (en)
Inventor
Masuhiro Yoshitake
Yoshinori Bamba
Original Assignee
J Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by J Pharma Co Ltd filed Critical J Pharma Co Ltd
Publication of BR112022002894A2 publication Critical patent/BR112022002894A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/009—Neutron capture therapy, e.g. using uranium or non-boron material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Rheumatology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

composição farmacêutica usada para um paciente tendo marcador genético específico. é fornecida uma composição farmacêutica compreendendo o-(5-amino-2-fenilbenzoxazol-7-il)metil-3,5-dicloro-l-tirosina, ou um sal farmaceuticamente aceitável do mesmo, para uso no tratamento de uma doença, como uma doença alérgica, uma doença autoimune ou uma doença inflamatória em um indivíduo, a composição farmacêutica sendo administrada ao indivíduo tendo um gene nat2 do tipo não rápido (lento e/ou intermediário).
BR112022002894A 2019-08-30 2020-08-31 Composição farmacêutica usada para um paciente tendo marcador genético específico BR112022002894A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019158681 2019-08-30
PCT/JP2020/032829 WO2021040043A1 (ja) 2019-08-30 2020-08-31 特定の遺伝子マーカーを有する患者に用いる医薬組成物

Publications (1)

Publication Number Publication Date
BR112022002894A2 true BR112022002894A2 (pt) 2022-05-10

Family

ID=74684222

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112022003220A BR112022003220A2 (pt) 2019-08-30 2020-08-31 Uma composição farmacêutica para tratar câncer usada para um paciente tendo marcador genético específico
BR112022002894A BR112022002894A2 (pt) 2019-08-30 2020-08-31 Composição farmacêutica usada para um paciente tendo marcador genético específico

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR112022003220A BR112022003220A2 (pt) 2019-08-30 2020-08-31 Uma composição farmacêutica para tratar câncer usada para um paciente tendo marcador genético específico

Country Status (10)

Country Link
US (2) US20220288036A1 (pt)
EP (2) EP4023296A1 (pt)
JP (3) JP6894155B2 (pt)
KR (2) KR20220054312A (pt)
CN (2) CN114340621A (pt)
BR (2) BR112022003220A2 (pt)
CA (2) CA3152369A1 (pt)
MX (2) MX2022002316A (pt)
TW (2) TW202122081A (pt)
WO (2) WO2021040043A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102328403B1 (ko) * 2017-11-07 2021-11-19 제이 파마 가부시끼가이샤 항pd-1 항체 혹은 항pd-l1 항체 요법의 주효성을 예측하는 방법, 암의 악성도를 평가하는 방법, 및 항pd-1 항체 혹은 항pd-l1 항체 요법의 주효성을 상승시키는 방법
WO2019130637A1 (ja) * 2017-12-28 2019-07-04 ジェイファーマ株式会社 がん治療薬

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2554775A1 (en) * 2004-01-30 2005-08-18 Chemgenex Pharmaceuticals, Inc. Naphthalimide dosing by n-acetyl transferase genotyping
JP2007209286A (ja) * 2006-02-10 2007-08-23 Sutaagen:Kk Ｓｔ合剤の副作用の危険性の判定方法
JPWO2008081537A1 (ja) * 2006-12-28 2010-04-30 株式会社ヒューマンセルシステムズ Ｌａｔ１阻害活性を有する芳香族アミノ酸誘導体、それを含有するｌａｔ１阻害活性剤及びその製造方法
JP5470665B1 (ja) * 2013-08-20 2014-04-16 ジェイファーマ株式会社 免疫抑制剤
JP6755457B2 (ja) * 2016-04-08 2020-09-16 株式会社Ｃｉｃｓ 合成アミノ酸の癌細胞内取り込みを保持する修飾法と正常細胞を保護する中性子捕捉療法
EP3860639B1 (en) * 2018-10-02 2023-12-06 Georgetown University An inhibitor of slc7a5 or lat1 for use in promoting remyelination of neurons

Also Published As

Publication number Publication date
EP4023298A4 (en) 2024-01-03
CA3152367A1 (en) 2021-03-04
MX2022002312A (es) 2022-06-02
MX2022002316A (es) 2022-06-02
KR20220054603A (ko) 2022-05-03
BR112022003220A2 (pt) 2022-05-17
WO2021040042A1 (ja) 2021-03-04
TW202122080A (zh) 2021-06-16
JP2021038214A (ja) 2021-03-11
JP2021121634A (ja) 2021-08-26
JP6894155B2 (ja) 2021-06-23
EP4023296A1 (en) 2022-07-06
KR20220054312A (ko) 2022-05-02
EP4023298A1 (en) 2022-07-06
WO2021040043A1 (ja) 2021-03-04
CN114340621A (zh) 2022-04-12
CN114364381A (zh) 2022-04-15
US20220288036A1 (en) 2022-09-15
TW202122081A (zh) 2021-06-16
CA3152369A1 (en) 2021-03-04
JPWO2021040043A1 (pt) 2021-03-04
US20220288035A1 (en) 2022-09-15

Similar Documents

Publication Publication Date Title
BR112022002894A2 (pt) Composição farmacêutica usada para um paciente tendo marcador genético específico
BR112022008375A2 (pt) Composto cíclico heterocíclico fundido substituído, método de preparação e uso farmacêutico deste
BR112022002580A2 (pt) Compostos inibitórios de rip1 e métodos para preparação e uso dos mesmos
BRPI0912411B8 (pt) uso de uma muteína de interleucina humana-2 (muteína de hil-2) e composição farmacêutica para o tratamento e/ou profilaxia de uma doença autoimune
BR112016008016A2 (pt) inibidores de kras g12c
ES2539790T3 (es) Métodos y composiciones para modular c-met hiperestabilizado
CL2007003520A1 (es) Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer.
BR112015026122A8 (pt) agente de polietileno glicol-il-10 (peg-il-10), seu uso, composição farmacêutica, contentor estéril e kit
BR112022002202A2 (pt) Métodos de tratar doença de fabry em pacientes tendo uma mutação no gene gla
BR112017026746A2 (pt) composições de liberação de fármacos implantáveis e métodos de uso dos mesmos
BR112016002651A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, combinação, formulação farmacêutica, métodos para exterminar uma micobactéria e/ou inibir a replicação das micobactérias, e para tratar uma infecção e uma doença, e, uso de um composto
CO6331425A2 (es) Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida
BR112015026247A8 (pt) composto em combinação com um análogo de citidina, composição farmacêutica que os compreende, uso dos mesmos e kit
BRPI0518993A2 (pt) composto ou um sal, solvato ou Éster farmaceuticamente aceitÁvel do mesmo, composiÇço farmacÊutica, e, uso de um composto
BR112014018485A8 (pt) Uso de laquinimod para tratar pacientes com a doença de crohn que falharam com a primeira linha de terapia anti-tnf
BR112018069515A2 (pt) uso de masitinibe para tratamento de uma subpopulação de pacientes com esclerose lateral amiotrófica
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
BR112017019343A2 (pt) uso de composições contendo peptídeo inibidor de mk2 para tratamento de câncer de pulmão de células não pequenas com as mesmas
BR112017011552A2 (pt) derivados de fgf21 e seu uso
BR112016004358A8 (pt) combinação farmacêutica de um inibidor de alk e um inibidor de cdk para tratamento de doenças proliferativas de célula, composição farmacêutica, seus usos, e kit
BR112022000382A2 (pt) Administração de agonista de sting e inibidores de checkpoint
BR112013010829B8 (pt) Composição farmacêutica intravenosa para proporcionar alívio da dor e/ou da inflamação
BR112012030621A2 (pt) compostos para o tratamento de doenças associadas com clostridim difficile
BR112017016428A2 (pt) ?composto ou sal farmaceuticamente aceitável, composição farmacêutica, uso de um composto ou sal farmaceuticamente aceitável, e, método para tratamento de um distúrbio hiperproliferativo maligno, de uma condição metabólica associada à obesidade, de um distúrbio autoimune ou de um distúrbio inflamatório?
BR112022004925A2 (pt) Composto, isômero do mesmo, solvato do mesmo, hidrato do mesmo ou sal farmaceuticamente aceitável do mesmo, método de preparação, uso do dito composto e composição farmacêutica

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]